Empowering CROs and pharma with precision patient selection - making cancer trials faster, clearer, and more successful.
Disease Landscape of lung cancer tumors. Point proximity relates to similar tumor biologies.
Powering the Next Generation of Precision Oncology Trials
At PointiList, we are working to dramatically improve the success of oncology clinical trials by using advanced RNA sequencing based technology to identify which patients are most likely to respond to treatment. This enables CROs and pharma partners to run faster, more efficient, and more reliable trials while reducing cost and risk. Seed-funded, we’re actively exploring pilot collaborations with CROs and trial sponsors.